SCHEMBL393773

SCHEMBL393773

Cc1c(C(=O)O)c(C)n(C(C(N)=O)N2CCCC2)c1C=C1C(=O)Nc2ccc(Nc3cccc(NC(=O)c4ccccc4)c3)cc21

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TLK2 Q86UE8 7/20 0.48
▸ GSK3B P49841 3/20 0.46
▸ NTRK1 P04629 3/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ AKT2 P31751 4/20 0.41
▸ PDPK1 O15530 2/20 0.41
▸ AURKA O14965 1/20 0.41
▸ NTRK3 Q16288 1/20 0.40
▸ RET P07949 1/20 0.40
▸ KIT P10721 1/20 0.40
▸ FLT4 P35916 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398246 0.94 NTRK1 (0.53) TLK2NTRK1AURKANTRK3KIT
SCHEMBL394537 0.94 NTRK1 (0.52) TLK2NTRK1AURKANTRK3KIT
SCHEMBL396166 0.93 TLK2 (0.47) TLK2GSK3BNTRK1JAK3AKT2
SCHEMBL396423 0.91 FLT3 (0.51) TLK2NTRK1AURKANTRK3KIT
SCHEMBL395533 0.90 FLT3 (0.48) TLK2GSK3BNTRK1JAK3KIT
SCHEMBL396893 0.89 FLT3 (0.47) TLK2GSK3BNTRK1JAK3KIT
SCHEMBL394471 0.88 NTRK1 (0.40) TLK2GSK3BNTRK1JAK3NTRK3
SCHEMBL396420 0.87 MAPK14 (0.45) TLK2GSK3BNTRK1NTRK3RET
SCHEMBL394096 0.87 NTRK1 (0.56) NTRK1AURKANTRK3KITFLT4
SCHEMBL394130 0.86 NTRK1 (0.56) NTRK1AURKANTRK3KITFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback